Hosting News »

13 November, 2020 – 4:32 pm |

“We made a decision to partner with GlobalSign, Europe’s longest serving Certificate Authority, as it offers the most trusted and inexpensive Code Signing and SSL security options now available in the digital certificate market,” Janmedia hosting director Alicja Baran related in an announcement. “GlobalSign’s digital certificates complement our existing product portfolio and we are anticipating […]

Read the full story »
Business News
Home » Health

Device could effectively alleviate menstrual cramp pain

Submitted by on 26 October, 2020 – 4:33 pm
Although most women experience mild pain during menstruation, for others the pain can be severe enough to interfere with daily activities and require medication. New research to be presented in 2009 the American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition will reveal the initial results of the security around a new device that can more effectively treat menstrual pain.

“The aim of our study was to find a better way to treat menstrual cramps,” said Giovanni M. Pauletti, Ph.D., associate professor at the University of Cincinnati and study presenter and president after the AAPS National Biotechnology Conference Planning Committee. “Existing oral drugs cause significant gastrointestinal side effects for women, creating additional discomfort while alleviating menstrual pain. The results of our Phase I clinical trials show that this new vaginal delivery device safely, at least 10 times more drug in the womb as a tablet of equivalent dose.

The study, sponsored by UMD, Inc., a drug delivery company in Cincinnati, and held in the Women’s Health Research, Inc. involving 18 study participants, aged 18-45 years with menstrual cycles between 25-30 days. During the follicular phase average of first menstrual cycle (days 7-11), nine study participants received an oral dose of 10 mg of ketorolac (Toradol ®), a non-steroidal anti-inflammatory drug, while nine women received a coated tampon 10 mg of ketorolac. During the second menstrual cycle, each subject received the opposite treatment.

The study results showed that vaginally administered medication does not cause significant side effects, but accumulates more efficiently in the uterine tissue is desired that the use of oral medication.

“While still early in our research, this study shows promising results that can help pave the way for new treatment options for women,” said Pauletti. “Clinical trials phase II study the efficacy of treatment to determine if the concentration of the drug is effective in reducing pain.”

Source: American Association of Pharmaceutical Scientists

Tags: , , , , ,

Leave a comment!

Add your comment below, or trackback from your own site. You can also Comments Feed via RSS.

Be nice. Keep it clean. Stay on topic. No spam.

You can use these tags:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> 

This is a Gravatar-enabled weblog. To get your own globally-recognized-avatar, please register at Gravatar.